Abstract
Cancer metabolism is currently re-evaluated by the research community with the aim to investigate possible opportunities for the development of targeted therapies. Firstly discovered by Warburg et al. in the beginning of the last century, it is now a widely accepted hypothesis that cancer cells possess a severely deregulated form of glycolysis also under aerobic conditions. Accompanied by a deregulated glycolysis is an increasing dependence on glucose and glutamine, this characteristic offers a striking opportunity for new kinds of anti-cancer drugs.
A feasible approach in this endeavour is the combined use of metabolic and transcriptomic information. Microarrays provide nowadays a reliable way for accessing the transcriptomic layer, even higher layers of biological information are in the scope. In this review we present the possibilities and also the limitations of this technique starting from the early phase of the microarray to the modern concepts of bioinformatics and systems biology. By highlighting also clinicopathological possibilities it is demonstrated that microarray technology is able to integrate various layers of biological information. Case studies incorporating aspects of cancer metabolism into therapy relevant applications and some potential new targets of cancer metabolism for novel cancer therapies are pointed out. These new cancer therapies can lead to the establishment of personalized medicine by use of custom based microarray platforms introducing treatment options in clinical decision making.
Keywords: Microarray analysis, cancer metabolism, systems biology, targeted therapies, personalized medicine
Current Pharmaceutical Design
Title:Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Volume: 19 Issue: 4
Author(s): Martin Koch, Michael Wiese
Affiliation:
Keywords: Microarray analysis, cancer metabolism, systems biology, targeted therapies, personalized medicine
Abstract: Cancer metabolism is currently re-evaluated by the research community with the aim to investigate possible opportunities for the development of targeted therapies. Firstly discovered by Warburg et al. in the beginning of the last century, it is now a widely accepted hypothesis that cancer cells possess a severely deregulated form of glycolysis also under aerobic conditions. Accompanied by a deregulated glycolysis is an increasing dependence on glucose and glutamine, this characteristic offers a striking opportunity for new kinds of anti-cancer drugs.
A feasible approach in this endeavour is the combined use of metabolic and transcriptomic information. Microarrays provide nowadays a reliable way for accessing the transcriptomic layer, even higher layers of biological information are in the scope. In this review we present the possibilities and also the limitations of this technique starting from the early phase of the microarray to the modern concepts of bioinformatics and systems biology. By highlighting also clinicopathological possibilities it is demonstrated that microarray technology is able to integrate various layers of biological information. Case studies incorporating aspects of cancer metabolism into therapy relevant applications and some potential new targets of cancer metabolism for novel cancer therapies are pointed out. These new cancer therapies can lead to the establishment of personalized medicine by use of custom based microarray platforms introducing treatment options in clinical decision making.
Export Options
About this article
Cite this article as:
Martin Koch, Michael Wiese , Accessing Cancer Metabolic Pathways by the Use of Microarray Technology, Current Pharmaceutical Design 2013; 19 (4) . https://dx.doi.org/10.2174/1381612811306040790
DOI https://dx.doi.org/10.2174/1381612811306040790 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons
Anti-Cancer Agents in Medicinal Chemistry The State-of-Art in Angiogenic Properties of Latex from Different Plant Species
Current Angiogenesis (Discontinued) Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry Coffea arabica Bean Extracts and Vitamin C: A Novel Combination Unleashes MCF-7 Cell Death
Current Pharmaceutical Biotechnology Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Regulatory Role of the α7nAChR in Cancer
Current Drug Targets The Influence of AIDS on the Morphometric and Immune Status of the Uterine Cervix of Autopsied Patients
Current HIV Research Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Dietary Supplementation of Curcumin Alleviates NF-κB-dependent Skeletal Muscle Wasting in Rat
Endocrine, Metabolic & Immune Disorders - Drug Targets SV40 and HIV Sequences in the Cerebrospinal Fluid of a Patient with AIDS Dementia Complex
Current HIV Research Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Immunological Aspects of Metritis in Dairy Cows: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Amygdalin Decreases Adhesion and Migration of MDA-MB-231 and MCF-7 Breast Cancer Cell Lines
Current Molecular Pharmacology Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design Combined Angiogenic and Osteogenic Factor Delivery for Bone Regenerative Engineering
Current Pharmaceutical Design